The Importance of CD44 as a Stem Cell Biomarker and Therapeutic Target in Cancer.
The Importance of CD44 as a Stem Cell Biomarker and Therapeutic Target in Cancer.
复制标题
DOI：
10.1155/2016/2087204
复制
发表时间：
2016
影响因子：
4.3
通讯作者：
Wilson GD
中科院分区：
文献类型：
--
作者：
Thapa R;Wilson GD
CD44是一种细胞表面透明质酸结合糖蛋白，在几乎所有上皮性肿瘤中都有不同程度的过度表达，在肿瘤的发生和转移中发挥重要作用。CD44是许多实体恶性肿瘤的癌症干细胞的引人注目的标志物。此外，HA和CD44的相互作用促进了EGFR介导的途径，从而导致实体瘤的肿瘤细胞生长、肿瘤细胞迁移和化疗耐药。越来越多的证据表明，主要的HA-CD44信号通路涉及CD44亚型的特定变体；然而，特定的变体几乎肯定取决于肿瘤细胞的类型和癌症进展的阶段。到目前为止的研究表明，使用针对不同CD44变异亚型的单抗，靶向抑制HA/CD44介导的信号转导，结合传统的放化疗，可能是未来治疗晚期恶性肿瘤最有利的治疗策略。因此，本文简要介绍了CD44主要变异亚型与肿瘤进展的关系，HA-CD44相互作用在肿瘤发生中的作用，以及针对CD44过表达的肿瘤细胞的策略。
CD44 is a cell surface HA-binding glycoprotein that is overexpressed to some extent by almost all tumors of epithelial origin and plays an important role in tumor initiation and metastasis. CD44 is a compelling marker for cancer stem cells of many solid malignancies. In addition, interaction of HA and CD44 promotes EGFR-mediated pathways, consequently leading to tumor cell growth, tumor cell migration, and chemotherapy resistance in solid cancers. Accumulating evidence indicates that major HA-CD44 signaling pathways involve a specific variant of CD44 isoforms; however, the particular variant almost certainly depends on the type of tumor cell and the stage of the cancer progression. Research to date suggests use of monoclonal antibodies against different CD44 variant isoforms and targeted inhibition of HA/CD44-mediated signaling combined with conventional radio/chemotherapy may be the most favorable therapeutic strategy for future treatments of advanced stage malignancies. Thus, this paper briefly focuses on the association of the major CD44 variant isoforms in cancer progression, the role of HA-CD44 interaction in oncogenic pathways, and strategies to target CD44-overexpressed tumor cells.